Delivery Order SPE2DB24D3013-SPE2DB25FFQTC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,990.49 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pens on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price, non-competitive delivery order represents a small-value pharmaceutical procurement executed under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,577.37 to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 ml pen (0.5 ml) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a injectable medication used in diabetes management, and this order represents a routine...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $16,728.19 on September 2, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen (0.5 mL) to be delivered to Conshohocken, Pennsylvania. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract is classified as a child award, indicating it is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed price delivery order represents a single-source procurement with no set-aside designation, issued under a competitive contracting mechanism. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,720.90 to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 ml pen (0.5 ml) on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication used for glycemic control in...
- The Defense Logistics Agency (DLA) awarded a $1,904.63 delivery order to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pens on May 5, 2025, with completion expected by May 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,225.77 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Mounjaro 5 mg/0.5 mL pens. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $53,547.94 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 ml pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price, competitively awarded delivery order—issued without a set-aside designation—represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a $1,360.45 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQTCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,879.15 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen (0.5 mL) with a completion date of September 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare programs and other federal customers including the Defense Health Agency and U.S. Coast Guard. Mounjaro, a diabetes medication, represents one of numerous therapeutic categories the contractor delivers under this strategic contract vehicle, demonstrating the company's critical role in federal medical procurement for defense-related healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/19/25 |